ACTUATE THERAPEUTICS, INC. — Form 8-K
Filed October 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Actuate Therapeutics completed an underwriting agreement with Newbridge Securities on Oct 26, 2026 to sell 30,985,900 common shares at $0.355/share plus 15,492,950 common warrant shares (exercise price $0.45), plus up to 4,647,885 option shares and 2,323,942 option warrant shares (15% over-allotment). Combined gross proceeds ~$20.4M before expenses; net to company ~$19.2M after 7% underwriting discount. Warrants exercisable 180 days post-effective through 5-year term; underwriter receives 3.5% warrant coverage.
Why this rating
Large capital raise (48% of $42M market cap) materially strengthens balance sheet; dilution and warrant overhang create headwinds; significant for company scale.
Price action (we called it positive)
before filing · preread $0.38 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.